Biosimulation Market By Product (Software, Services), By Application (Drug Development, Drug Discovery, Others), By Delivery model (Subscription Model, Ownership Model), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization (CROs), Academic and Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

Biosimulation Market

The computer-assisted simulation of biological processes that are essential to human biology is known as biosimulation. The goal of biosimulation is to offer model-based predictions of the dynamics and behavior of a biological system. A simulation model translates the knowledge about the biological system into mathematical equations. In the initial stage of the drug development process, one is anticipated to use the simulation model to test any hypothesis and change the product in order to optimize its function or estimate the chances that a given agent is projected to function as a drug, even before the first molecule is produced. The simulation model is anticipated to be used as a vehicle to define an effective test protocol and to check that information obtained from tests is consistent.                

Key factors driving the growth of the biosimulation market include growing adoption of biosimulation software, technological advancements in biosimulation software and increase in demand to curtail drug development and discovery costs.  

Biosimulation plays a crucial role in drug discovery and development. It enables researchers to anticipate the efficacy of possible medication candidates and enhance their qualities by simulating their effects on biological systems. It shortens the time and expense involved with conventional trial-and-error methods by modeling the interactions between medications and target molecules. Moreover, it assists in identifying relevant drug candidates.  

The adoption of biosimulation software by regulatory authorities is projected to fuel market expansion. Biosimulation is being widely used to model cellular processes, diagnose disease, and modify cells. The market growth for biosimulation is being significantly accelerated by recent developments in biomedical simulation technology. The key market players in the biosimulation sector have concentrated on improving the quality of biosimulation through the use of simulation models, leveraging tools, and software engineering best practices. The trend of model engineering has gathered significant pace in recent years and is anticipated to increase impressively over the upcoming years. The existing fundamental problems with biosimulation, such as reuse, readability, and repeatability, are expected to be addressed by market participants. Major players such as Simulation Plus and Certara are being driven by the rise in demand for the market of biosimulation to concentrate on expanding their global footprint by using inorganic growth strategies. 

Moreover, the process of bringing a new drug to market is time-consuming, expensive, and fraught with uncertainties. The high cost of drug discovery and development process and surge in demand to reduce the costs of drug discovery and development are the major factors that increases the demand for biosimulation software and hence propel the growth of the biosimulation market. For instance, according to the report published by Proclinica, a global leader in life science recruitment & consulting solutions in September 2020, it has been reported that with complexity of diseases becoming more apparent, it has become increasingly expensive to develop new treatments. On average top pharma companies spend around 17% of revenues on research and development, making the pharmaceutical industry one of the biggest investors in this area. This is only set to keep increasing, with a recent report stating R&D costs are expected to grow by 3% each year, reaching over $203 billion by 2024. In addition, on average it costs nearly $4 billion to develop a new medicine but is projected to sometimes exceed $10 billion. Pharmaceutical companies differ from companies in other industries as the medicine research and development process involves great risk. For instance, only one out of every 10,000 discovered compounds actually get marketing authorization.   

Furthermore, the high cost of drug development is problematic for an industry being pressured to cut costs. It makes it harder to advance new ideas and create new cures. Thus, it is essential for the pharma companies to continue to evolve medicine to help improve lives and reduce the incidence of disease and save healthcare costs in the long run. These factors are anticipated to increase the demand for biosimulation software that boosts the growth of the market. 

The market also offers growth opportunities to the key players in the market.  The rise in demand for biosimilar software in different therapeutic applications such as rheumatoid arthritis and blood disorders and surge in awareness regarding emerging applications of biosimulation software in various fields such as defense, industrial bioprocessing, nutraceutical, and agri-food productions globally fuel the growth of the biosimulation market.   

In addition, rise in the demand of personalized medicine and surge in technological advancement such as scientific breakthroughs in decoding the human genome, and data computing has increased the demand for biosimulation software and hence propel the growth of the market. For instance, according to a report published by Tata Consultancy Services in 2022, medical imaging has helped researchers generate valuable insights to treat chronic and critical diseases such as cancer. Moreover, the existing need to reduce patient morbidity and mortality drives personalized medicine initiatives to achieve an efficient mode of therapy.  

Furthermore, according to a report published by the Personalized Medicine Coalition (PMC), nearly 35% of USFDA new drug approvals in 2017 were personalized medicines. Much of this observed growth in personalized medicine development initiatives is anticipated to be attributed to technological advancements that have increased the demand for biosimulation software. This has allowed the healthcare industry to successfully identify patient subgroups and engineer drugs targeted towards them. All these factors are collectively expected to open new avenues for the growth of the biosimulation market during the forecast period. 

The global biosimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into software and services. On the basis of delivery model, the market is segmented into subscription model and ownership model. On the basis of application, it is segregated into drug development, drug discovery and others. On the basis of end user, it is segmented into pharmaceutical and biotechnology companies, contract research organization (CROs) and academic and research institutes. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).          

The report provides competitive analysis and profiles of the major players in the biosimulation market, such as Dassault Systemes, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PLC, INOSIM Software GmbH, Schrodinger, Inc. Simulation Plus Inc, and Cadence Design Systems, Inc. 

Key Market Insights 

By product, the software segment is expected to experience rapid growth in the market and is estimated to reach $7,057.24 million by 2032, with a CAGR of 16.0%. However, the services segment is estimated to be growing with a significant CAGR of 15.2% during the forecast period. 

By application, the drug discovery segment dominated the global market. However, the drug development segment is expected to grow with a significant CAGR of 15.4% during the forecast period.  

By delivery model, the ownership model segment dominated the global market. However, the subscription model segment is expected to grow with a significant CAGR of 15.1% during the forecast period. 

By end user, the pharmaceutical and biotechnology companies segment dominated the global market. However, the contract research organizations segment is expected to grow with a significant CAGR of 15.8% during the forecast period. 

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 17.0% during the forecast period. 

 

Overview

The Biosimulation Market was valued for $2,452.31 million in 2022 and is estimated to reach $10,573.52 million by 2032, exhibiting a CAGR of 15.8% from 2023 to 2032. Biosimulation uses computer-based mathematical simulations to replicate biological processes, dynamics, and systems. Model-based predictions software such as biosimulation allow researchers to gather important data about how biological systems behave without having to conduct such tests in living organisms, including humans and animals.  

Pre-clinical testing of novel medicines, lead identification and optimization, target identification and validation are some primary areas where biosimulation is being used in drug R&D. Biosimulation forms the backbone of “virtual” drug trials, whose aim is to accurately predict the way medicines and diseases behave in the body by applying principles from biology, chemistry, and pharmacology with proprietary algorithms. In addition, this work includes gathering critical insights concerning drug interactions, safe dosing, toxicity predictions, and more.  

Major factors that drive the growth of the global biosimulation market include an increase in demand for drug discovery and development, rise in need for personalized medicines, and surge in technological advancement in biosimulation software and devices. For instance, in June 2022, Certara, a global leader in biosimulation, released the new versions of immunogenicity (IG), immuno-oncology (IO) and vaccine simulators to help predict how drugs work and address key questions in the development of novel biologic therapies.  

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, diabetes, Alzheimer's, cardiovascular disease, kidney disorders, and various others are the major factors that increase the demand for biosimulation software and hence propel the growth of the market. In addition, rise in demand to reduce drug discovery and development costs and increase in penetration of biosimulation software in contract research organization (CROs) and academic research institutes for drug discovery and development are the major factors that boost the growth of the biosimulation market.   

However, the lack of standardized formats, protocols, and interoperability between different simulation platforms and limited awareness and education about biosimulation techniques among researchers and healthcare professionals restrain the growth of the biosimulation market. On the contrary, the expanding applications and increased use of personalized medicine and biosimulation solutions for pediatric drug development are expected to provide additional opportunities for the biosimulation market to grow in the coming years.   

The global biosimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into software and services. On the basis of delivery model, the market is segmented into subscription model and ownership model. On the basis of application, it is segregated into drug development, drug discovery and others. On the basis of end user, it is segmented into pharmaceutical and biotechnology companies, contract research organization (CROs) and academic and research institutes. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).   

The major players profiled in the report are Dassault Systemes, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PLC, INOSIM Software GmbH, Schrodinger, Inc. Simulation Plus Inc, and Cadence Design Systems, Inc. The key players such as Simulation Plus Inc, Cadence Design Systems Inc, VeriSIM Life, Certara Inc, Schrodinger Inc, and Genedata AG have adopted product launch, acquisition, collaboration, partnership, and business expansion as major developmental strategies to improve the product portfolio of the biosimulation market. 

 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimulation market analysis from 2022 to 2032 to identify the prevailing biosimulation market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the biosimulation market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global biosimulation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

○ INOSIM Software Gmb

Scope of Biosimulation Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Low bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Growth in adoption of biosimulation software

3.4.1.2. Technological advancements in biosimulation software

3.4.1.3. Increase in demand to curtail drug discovery and development costs

3.4.2. Restraints

3.4.2.1. Lack of standardization and interoperability

3.4.3. Opportunities

3.4.3.1. Expansion of applications of biosimulation and increase in demand for personalized medicine.

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Software

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Services

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Drug Development

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Drug Discovery

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Subscription Model

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Ownership Model

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast

7.2. Pharmaceutical and Biotechnology Companies

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Contract Research Organization (CROs)

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Academic and Research Institutes

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America

8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by Product

8.2.3. Market size and forecast, by Application

8.2.4. Market size and forecast, by Delivery model

8.2.5. Market size and forecast, by End User

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Market size and forecast, by Product

8.2.6.1.2. Market size and forecast, by Application

8.2.6.1.3. Market size and forecast, by Delivery model

8.2.6.1.4. Market size and forecast, by End User

8.2.6.2. Canada

8.2.6.2.1. Market size and forecast, by Product

8.2.6.2.2. Market size and forecast, by Application

8.2.6.2.3. Market size and forecast, by Delivery model

8.2.6.2.4. Market size and forecast, by End User

8.2.6.3. Mexico

8.2.6.3.1. Market size and forecast, by Product

8.2.6.3.2. Market size and forecast, by Application

8.2.6.3.3. Market size and forecast, by Delivery model

8.2.6.3.4. Market size and forecast, by End User

8.3. Europe

8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by Product

8.3.3. Market size and forecast, by Application

8.3.4. Market size and forecast, by Delivery model

8.3.5. Market size and forecast, by End User

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Market size and forecast, by Product

8.3.6.1.2. Market size and forecast, by Application

8.3.6.1.3. Market size and forecast, by Delivery model

8.3.6.1.4. Market size and forecast, by End User

8.3.6.2. France

8.3.6.2.1. Market size and forecast, by Product

8.3.6.2.2. Market size and forecast, by Application

8.3.6.2.3. Market size and forecast, by Delivery model

8.3.6.2.4. Market size and forecast, by End User

8.3.6.3. UK

8.3.6.3.1. Market size and forecast, by Product

8.3.6.3.2. Market size and forecast, by Application

8.3.6.3.3. Market size and forecast, by Delivery model

8.3.6.3.4. Market size and forecast, by End User

8.3.6.4. Italy

8.3.6.4.1. Market size and forecast, by Product

8.3.6.4.2. Market size and forecast, by Application

8.3.6.4.3. Market size and forecast, by Delivery model

8.3.6.4.4. Market size and forecast, by End User

8.3.6.5. Spain

8.3.6.5.1. Market size and forecast, by Product

8.3.6.5.2. Market size and forecast, by Application

8.3.6.5.3. Market size and forecast, by Delivery model

8.3.6.5.4. Market size and forecast, by End User

8.3.6.6. Rest of Europe

8.3.6.6.1. Market size and forecast, by Product

8.3.6.6.2. Market size and forecast, by Application

8.3.6.6.3. Market size and forecast, by Delivery model

8.3.6.6.4. Market size and forecast, by End User

8.4. Asia-Pacific

8.4.1. Key market trends, growth factors and opportunities

8.4.2. Market size and forecast, by Product

8.4.3. Market size and forecast, by Application

8.4.4. Market size and forecast, by Delivery model

8.4.5. Market size and forecast, by End User

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Market size and forecast, by Product

8.4.6.1.2. Market size and forecast, by Application

8.4.6.1.3. Market size and forecast, by Delivery model

8.4.6.1.4. Market size and forecast, by End User

8.4.6.2. China

8.4.6.2.1. Market size and forecast, by Product

8.4.6.2.2. Market size and forecast, by Application

8.4.6.2.3. Market size and forecast, by Delivery model

8.4.6.2.4. Market size and forecast, by End User

8.4.6.3. Australia

8.4.6.3.1. Market size and forecast, by Product

8.4.6.3.2. Market size and forecast, by Application

8.4.6.3.3. Market size and forecast, by Delivery model

8.4.6.3.4. Market size and forecast, by End User

8.4.6.4. India

8.4.6.4.1. Market size and forecast, by Product

8.4.6.4.2. Market size and forecast, by Application

8.4.6.4.3. Market size and forecast, by Delivery model

8.4.6.4.4. Market size and forecast, by End User

8.4.6.5. South Korea

8.4.6.5.1. Market size and forecast, by Product

8.4.6.5.2. Market size and forecast, by Application

8.4.6.5.3. Market size and forecast, by Delivery model

8.4.6.5.4. Market size and forecast, by End User

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Market size and forecast, by Product

8.4.6.6.2. Market size and forecast, by Application

8.4.6.6.3. Market size and forecast, by Delivery model

8.4.6.6.4. Market size and forecast, by End User

8.5. LAMEA

8.5.1. Key market trends, growth factors and opportunities

8.5.2. Market size and forecast, by Product

8.5.3. Market size and forecast, by Application

8.5.4. Market size and forecast, by Delivery model

8.5.5. Market size and forecast, by End User

8.5.6. Market size and forecast, by country

8.5.6.1. Latin America

8.5.6.1.1. Market size and forecast, by Product

8.5.6.1.2. Market size and forecast, by Application

8.5.6.1.3. Market size and forecast, by Delivery model

8.5.6.1.4. Market size and forecast, by End User

8.5.6.2. Middle East

8.5.6.2.1. Market size and forecast, by Product

8.5.6.2.2. Market size and forecast, by Application

8.5.6.2.3. Market size and forecast, by Delivery model

8.5.6.2.4. Market size and forecast, by End User

8.5.6.3. Africa

8.5.6.3.1. Market size and forecast, by Product

8.5.6.3.2. Market size and forecast, by Application

8.5.6.3.3. Market size and forecast, by Delivery model

8.5.6.3.4. Market size and forecast, by End User

9.1. Introduction

9.2. Top winning strategies

9.3. Product Mapping of Top 10 Player

9.4. Competitive Dashboard

9.5. Competitive Heatmap

9.6. Top player positioning, 2022

10.1. Certara, Inc.

10.1.1. Company overview

10.1.2. Key Executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Business performance

10.1.0. Key strategic moves and developments

10.2. Dassault Systemes

10.2.1. Company overview

10.2.2. Key Executives

10.2.3. Company snapshot

10.2.4. Operating business segments

10.2.5. Product portfolio

10.2.6. Business performance

10.3. Simulations Plus, Inc.

10.3.1. Company overview

10.3.2. Key Executives

10.3.3. Company snapshot

10.3.4. Operating business segments

10.3.5. Product portfolio

10.3.6. Business performance

10.3.0. Key strategic moves and developments

10.4. Genedata AG

10.4.1. Company overview

10.4.2. Key Executives

10.4.3. Company snapshot

10.4.4. Operating business segments

10.4.5. Product portfolio

10.4.0. Key strategic moves and developments

10.5. SimBioSys

10.5.1. Company overview

10.5.2. Key Executives

10.5.3. Company snapshot

10.5.4. Operating business segments

10.5.5. Product portfolio

10.6. Physiomics Plc

10.6.1. Company overview

10.6.2. Key Executives

10.6.3. Company snapshot

10.6.4. Operating business segments

10.6.5. Product portfolio

10.6.6. Business performance

10.7. INOSIM Software GmbH

10.7.1. Company overview

10.7.2. Key Executives

10.7.3. Company snapshot

10.7.4. Operating business segments

10.7.5. Product portfolio

10.8. VeriSIM Life

10.8.1. Company overview

10.8.2. Key Executives

10.8.3. Company snapshot

10.8.4. Operating business segments

10.8.5. Product portfolio

10.8.0. Key strategic moves and developments

10.9. Schrodinger, Inc.

10.9.1. Company overview

10.9.2. Key Executives

10.9.3. Company snapshot

10.9.4. Operating business segments

10.9.5. Product portfolio

10.9.6. Business performance

10.9.0. Key strategic moves and developments

10.10. Cadence Design Systems, Inc.

10.10.1. Company overview

10.10.2. Key Executives

10.10.3. Company snapshot

10.10.4. Operating business segments

10.10.5. Product portfolio

10.10.6. Business performance

10.10.0. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 02. BIOSIMULATION MARKET FOR SOFTWARE, BY REGION, 2022-2032 ($MILLION)

TABLE 03. BIOSIMULATION MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)

TABLE 04. GLOBAL BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 05. BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022-2032 ($MILLION)

TABLE 06. BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2032 ($MILLION)

TABLE 07. BIOSIMULATION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 09. BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY REGION, 2022-2032 ($MILLION)

TABLE 10. BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY REGION, 2022-2032 ($MILLION)

TABLE 11. GLOBAL BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 12. BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)

TABLE 13. BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY REGION, 2022-2032 ($MILLION)

TABLE 14. BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)

TABLE 15. BIOSIMULATION MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 18. NORTH AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 19. NORTH AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 20. NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 21. U.S. BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 22. U.S. BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 23. U.S. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 24. U.S. BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 25. CANADA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 26. CANADA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 27. CANADA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 28. CANADA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 29. MEXICO BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 30. MEXICO BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 31. MEXICO BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 32. MEXICO BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 33. EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 34. EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 35. EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 36. EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 37. EUROPE BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 38. GERMANY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 39. GERMANY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 40. GERMANY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 41. GERMANY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 42. FRANCE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 43. FRANCE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 44. FRANCE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 45. FRANCE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 46. UK BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 47. UK BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 48. UK BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 49. UK BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 50. ITALY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 51. ITALY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 52. ITALY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 53. ITALY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 54. SPAIN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 55. SPAIN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 56. SPAIN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 57. SPAIN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 58. REST OF EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 59. REST OF EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 60. REST OF EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 61. REST OF EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 62. ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 63. ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 64. ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 65. ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 66. ASIA-PACIFIC BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 67. JAPAN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 68. JAPAN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 69. JAPAN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 70. JAPAN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 71. CHINA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 72. CHINA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 73. CHINA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 74. CHINA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 75. AUSTRALIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 76. AUSTRALIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 77. AUSTRALIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 78. AUSTRALIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 79. INDIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 80. INDIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 81. INDIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 82. INDIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 83. SOUTH KOREA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 84. SOUTH KOREA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 85. SOUTH KOREA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 86. SOUTH KOREA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 87. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 88. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 89. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 90. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 91. LAMEA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 92. LAMEA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 93. LAMEA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 94. LAMEA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 95. LAMEA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 96. LATIN AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 97. LATIN AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 98. LATIN AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 99. LATIN AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 100. MIDDLE EAST BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 101. MIDDLE EAST BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 102. MIDDLE EAST BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 103. MIDDLE EAST BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 104. AFRICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 105. AFRICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 106. AFRICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)

TABLE 107. AFRICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 108. CERTARA, INC.: KEY EXECUTIVES

TABLE 109. CERTARA, INC.: COMPANY SNAPSHOT

TABLE 110. CERTARA, INC.: SERVICE SEGMENTS

TABLE 111. CERTARA, INC.: PRODUCT PORTFOLIO

TABLE 112. CERTARA, INC.: KEY STRATERGIES

TABLE 113. DASSAULT SYSTEMES: KEY EXECUTIVES

TABLE 114. DASSAULT SYSTEMES: COMPANY SNAPSHOT

TABLE 115. DASSAULT SYSTEMES: PRODUCT SEGMENTS

TABLE 116. DASSAULT SYSTEMES: PRODUCT PORTFOLIO

TABLE 117. SIMULATIONS PLUS, INC.: KEY EXECUTIVES

TABLE 118. SIMULATIONS PLUS, INC.: COMPANY SNAPSHOT

TABLE 119. SIMULATIONS PLUS, INC.: SERVICE SEGMENTS

TABLE 120. SIMULATIONS PLUS, INC.: PRODUCT PORTFOLIO

TABLE 121. SIMULATIONS PLUS, INC.: KEY STRATERGIES

TABLE 122. GENEDATA AG: KEY EXECUTIVES

TABLE 123. GENEDATA AG: COMPANY SNAPSHOT

TABLE 124. GENEDATA AG: PRODUCT SEGMENTS

TABLE 125. GENEDATA AG: PRODUCT PORTFOLIO

TABLE 126. GENEDATA AG: KEY STRATERGIES

TABLE 127. SIMBIOSYS: KEY EXECUTIVES

TABLE 128. SIMBIOSYS: COMPANY SNAPSHOT

TABLE 129. SIMBIOSYS: SERVICE SEGMENTS

TABLE 130. SIMBIOSYS: PRODUCT PORTFOLIO

TABLE 131. PHYSIOMICS PLC: KEY EXECUTIVES

TABLE 132. PHYSIOMICS PLC: COMPANY SNAPSHOT

TABLE 133. PHYSIOMICS PLC: SERVICE SEGMENTS

TABLE 134. PHYSIOMICS PLC: PRODUCT PORTFOLIO

TABLE 135. INOSIM SOFTWARE GMBH: KEY EXECUTIVES

TABLE 136. INOSIM SOFTWARE GMBH: COMPANY SNAPSHOT

TABLE 137. INOSIM SOFTWARE GMBH: SERVICE SEGMENTS

TABLE 138. INOSIM SOFTWARE GMBH: PRODUCT PORTFOLIO

TABLE 139. VERISIM LIFE: KEY EXECUTIVES

TABLE 140. VERISIM LIFE: COMPANY SNAPSHOT

TABLE 141. VERISIM LIFE: SERVICE SEGMENTS

TABLE 142. VERISIM LIFE: PRODUCT PORTFOLIO

TABLE 143. VERISIM LIFE: KEY STRATERGIES

TABLE 144. SCHRODINGER, INC.: KEY EXECUTIVES

TABLE 145. SCHRODINGER, INC.: COMPANY SNAPSHOT

TABLE 146. SCHRODINGER, INC.: SERVICE SEGMENTS

TABLE 147. SCHRODINGER, INC.: PRODUCT PORTFOLIO

TABLE 148. SCHRODINGER, INC.: KEY STRATERGIES

TABLE 149. CADENCE DESIGN SYSTEMS, INC.: KEY EXECUTIVES

TABLE 150. CADENCE DESIGN SYSTEMS, INC.: COMPANY SNAPSHOT

TABLE 151. CADENCE DESIGN SYSTEMS, INC.: SERVICE SEGMENTS

TABLE 152. CADENCE DESIGN SYSTEMS, INC.: PRODUCT PORTFOLIO

TABLE 153. CADENCE DESIGN SYSTEMS, INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. BIOSIMULATION MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF BIOSIMULATION MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN BIOSIMULATION MARKET (2023-2032)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW THREAT OF NEW ENTRANTS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW INTENSITY OF RIVALRY

FIGURE 08. LOW BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL BIOSIMULATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. BIOSIMULATION MARKET, BY PRODUCT, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SOFTWARE, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SERVICES, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. BIOSIMULATION MARKET, BY APPLICATION, 2022(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. BIOSIMULATION MARKET, BY END USER, 2022(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY COUNTRY 2022 AND 2032(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)

FIGURE 24. BIOSIMULATION MARKET BY REGION, 2022(%)

FIGURE 25. U.S. BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 26. CANADA BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 27. MEXICO BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 28. GERMANY BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 29. FRANCE BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 30. UK BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 31. ITALY BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 32. SPAIN BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 33. REST OF EUROPE BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 34. JAPAN BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 35. CHINA BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 36. AUSTRALIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 37. INDIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 38. SOUTH KOREA BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 39. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 40. LATIN AMERICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 41. MIDDLE EAST BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 42. AFRICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)

FIGURE 43. TOP WINNING STRATEGIES, BY YEAR (2020-2023)

FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)

FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)

FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 47. COMPETITIVE DASHBOARD

FIGURE 48. COMPETITIVE HEATMAP: BIOSIMULATION MARKET

FIGURE 49. TOP PLAYER POSITIONING, 2022

FIGURE 50. CERTARA, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 51. CERTARA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 52. CERTARA, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 53. DASSAULT SYSTEMES: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 54. DASSAULT SYSTEMES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 55. DASSAULT SYSTEMES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 56. SIMULATIONS PLUS, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 57. SIMULATIONS PLUS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. SIMULATIONS PLUS, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 59. PHYSIOMICS PLC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 60. SCHRODINGER, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 61. SCHRODINGER, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. SCHRODINGER, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. CADENCE DESIGN SYSTEMS, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 64. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 65. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY REGION, 2022 (%